{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:43:52Z","timestamp":1794854632806,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_179342"],"award-info":[{"award-number":["310030_179342"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Peptidic radiotracers are preferentially excreted through the kidneys, which often results in high persistent renal retention\u00a0of radioactivity, limiting or even preventing therapeutic clinical translation of these radiotracers. Exendin-4, which targets the glucagon-like-peptide 1 receptor (GLP-1R) overexpressed in insulinomas and in congenital hyperinsulinism, is an example thereof. The use of the tripeptide MVK, which is readily cleaved between methionine and valine by neprilysin at the renal brush border membrane, already showed promising results in reducing kidney uptake as reported in the literature. Based on our previous findings we were interested how linker variants with multiple copies of the MV-motive influence renal washout of radiolabelled exendin-4.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three exendin-4 derivatives, carrying either one MVK, a MV-MVK or a MVK-MVK linker were synthesized and compared to a reference compound lacking a cleavable linker. In vivo results of a biodistribution in GLP-1R overexpressing tumour bearing mice at 24 h post-injection demonstrated a significant reduction (at least 57%) of renal retention of all <jats:sup>111<\/jats:sup>In-labeled exendin-4 compounds equipped with a cleavable linker compared to the reference compound. While the insertion of the single linker MVK led to a reduction in kidney uptake of 70%, the dual approach with the linker MV-MVK slightly, but not significantly enhanced this effect, with 77% reduction in kidney uptake compared to the reference. In vitro IC<jats:sub>50<\/jats:sub> and cell uptake studies were conducted and demonstrated that though the cleavable linkers negatively influenced the affinity towards the GLP-1R, cell uptake remained largely unaffected, except for the MV-MVK cleavable linker conjugate, which displayed lower cell uptake than the other compounds. Importantly, the tumour uptake in the biodistribution study was not significantly affected with 2.9, 2.5, 3.2 and 1.5% iA\/g for radiolabelled Ex4, MVK-Ex4, MV-MVK-Ex4 and MVK-MVK-Ex4, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Cleavable linkers are highly efficient in reducing the radioactivity burden in the kidney. Though the dual linker approach using the instillation of MV-MVK or MVK-MVK between exendin-4 and the radiometal chelator did not significantly outperform the single cleavable linker MVK, further structural optimization or the combination of different cleavable linkers could be a stepping stone in reducing radiation-induced nephrotoxicity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41181-023-00206-2","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T09:01:59Z","timestamp":1693818119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK"],"prefix":"10.1186","volume":"8","author":[{"given":"Belinda","family":"Trachsel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Valpreda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Schibli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjing","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1110-2665","authenticated-orcid":false,"given":"Martin","family":"B\u00e9h\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"issue":"1","key":"206_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0968-0896(01)00263-2","volume":"10","author":"NH Andersen","year":"2002","unstructured":"Andersen NH, Brodsky Y, Neidigh JW, Prickett KS. Medium-dependence of the secondary structure of exendin-4 and glucagon-like-peptide-1. Bioorg Med Chem. 2002;10(1):79\u201385.","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"206_CR2","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1097\/RLU.0000000000003124","volume":"45","author":"K Antwi","year":"2020","unstructured":"Antwi K, Hepprich M, Muller NA, Reubi JC, Fani M, Rottenburger C, et al. Pitfalls in the detection of insulinomas with glucagon-like peptide-1 receptor imaging. Clin Nucl Med. 2020;45(9):e386\u201392.","journal-title":"Clin Nucl Med"},{"key":"206_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.nucmedbio.2020.03.001","volume":"92","author":"Y Arano","year":"2020","unstructured":"Arano Y. Renal brush border strategy: a developing procedure to reduce renal radioactivity levels of radiolabeled polypeptides. Nucl Med Biol. 2020;92:149\u201355.","journal-title":"Nucl Med Biol"},{"issue":"17","key":"206_CR4","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.3390\/molecules25173854","volume":"25","author":"S Bendre","year":"2020","unstructured":"Bendre S, Zhang Z, Kuo HT, Rousseau J, Zhang C, Merkens H, et al. Evaluation of Met-Val-Lys as a renal brush border enzyme-cleavable linker to reduce kidney uptake of (68)Ga-Labeled DOTA-conjugated peptides and peptidomimetics. Molecules. 2020;25(17):3854.","journal-title":"Molecules."},{"issue":"2","key":"206_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2967\/jnumed.121.262327","volume":"63","author":"M Boss","year":"2022","unstructured":"Boss M, Rottenburger C, Brenner W, Blankenstein O, Prasad V, Prasad S, et al. (68)Ga-NODAGA-Exendin-4 PET\/CT improves the detection of focal congenital hyperinsulinism. J Nucl Med. 2022;63(2):310\u20135.","journal-title":"J Nucl Med"},{"issue":"11","key":"206_CR6","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1210\/jc.2009-1082","volume":"94","author":"E Christ","year":"2009","unstructured":"Christ E, Wild D, Forrer F, Brandle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94(11):4398\u2013405.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"206_CR7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000201054","volume":"54","author":"R Goke","year":"1993","unstructured":"Goke R, Fehmann HC, Linn T, Schmidt H, Engvi IJ, Goke B. Exendin-4 is a high-potency agonist and truncated Exendin (9-39) amide an antagonist at the Glp-1 (7-36) amide receptor of insulin-secreting beta-cells. Digestion. 1993;54(6):347.","journal-title":"Digestion"},{"issue":"4","key":"206_CR8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.106.036020","volume":"48","author":"M Gotthardt","year":"2007","unstructured":"Gotthardt M, van Eerd-Vismale J, Oyen WJ, de Jong M, Zhang H, Rolleman E, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med. 2007;48(4):596\u2013601.","journal-title":"J Nucl Med"},{"issue":"3","key":"206_CR9","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1021\/acs.molpharmaceut.2c00068","volume":"19","author":"S Iikuni","year":"2022","unstructured":"Iikuni S, Kamei I, Ohara T, Watanabe H, Ono M. Development of an (111)In-labeled glucagon-like peptide-1 receptor-targeting exendin-4 derivative that exhibits reduced renal uptake. Mol Pharm. 2022;19(3):1019\u201327.","journal-title":"Mol Pharm"},{"issue":"10","key":"206_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/jlcr.3750","volume":"62","author":"TJP Jansen","year":"2019","unstructured":"Jansen TJP, van Lith SAM, Boss M, Brom M, Joosten L, Behe M, et al. Exendin-4 analogs in insulinoma theranostics. J Label Comp Radiopharm. 2019;62(10):656\u201372.","journal-title":"J Label Comp Radiopharm"},{"issue":"4","key":"206_CR11","doi-asserted-by":"publisher","first-page":"e0123443","DOI":"10.1371\/journal.pone.0123443","volume":"10","author":"A Jodal","year":"2015","unstructured":"Jodal A, Pape F, Becker-Pauly C, Maas O, Schibli R, Behe M. Evaluation of (1)(1)(1)in-labelled exendin-4 derivatives containing different meprin beta-specific cleavable linkers. PLoS ONE. 2015;10(4):e0123443.","journal-title":"PLoS ONE"},{"issue":"9","key":"206_CR12","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1021\/acs.molpharmaceut.9b00271","volume":"16","author":"SAM Kaeppeli","year":"2019","unstructured":"Kaeppeli SAM, Jodal A, Gotthardt M, Schibli R, Behe M. Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting. Mol Pharm. 2019;16(9):3760\u20139.","journal-title":"Mol Pharm"},{"issue":"1","key":"206_CR13","doi-asserted-by":"publisher","first-page":"e0189901","DOI":"10.1371\/journal.pone.0189901","volume":"13","author":"J Moeller","year":"2018","unstructured":"Moeller J, Denisin AK, Sim JY, Wilson RE, Ribeiro AJS, Pruitt BL. Controlling cell shape on hydrogels using lift-off protein patterning. PLoS ONE. 2018;13(1):e0189901.","journal-title":"PLoS ONE"},{"issue":"3","key":"206_CR14","doi-asserted-by":"publisher","first-page":"220950","DOI":"10.1098\/rsos.220950","volume":"10","author":"E Murce","year":"2023","unstructured":"Murce E, de Blois E, van den Berg S, de Jong M, Seimbille Y. Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK\/MVK cleavable linkers. R Soc Open Sci. 2023;10(3):220950.","journal-title":"R Soc Open Sci"},{"issue":"12","key":"206_CR15","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1021\/acs.jmedchem.8b00198","volume":"61","author":"C Suzuki","year":"2018","unstructured":"Suzuki C, Uehara T, Kanazawa N, Wada S, Suzuki H, Arano Y. Preferential cleavage of a tripeptide linkage by enzymes on renal brush border membrane to reduce renal radioactivity levels of radiolabeled antibody fragments. J Med Chem. 2018;61(12):5257\u201368.","journal-title":"J Med Chem"},{"issue":"11","key":"206_CR16","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1021\/bc5004058","volume":"25","author":"T Uehara","year":"2014","unstructured":"Uehara T, Rokugawa T, Kinoshita M, Nemoto S, Fransisco Lazaro GG, Hanaoka H, et al. (67\/68)Ga-labeling agent that liberates (67\/68)Ga-NOTA-methionine by lysosomal proteolysis of parental low molecular weight polypeptides to reduce renal radioactivity levels. Bioconjug Chem. 2014;25(11):2038\u201345.","journal-title":"Bioconjug Chem"},{"issue":"14","key":"206_CR17","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1158\/1078-0432.CCR-18-0123","volume":"24","author":"T Uehara","year":"2018","unstructured":"Uehara T, Yokoyama M, Suzuki H, Hanaoka H, Arano Y. A gallium-67\/68-labeled antibody fragment for immuno-SPECT\/PET shows low renal radioactivity without loss of tumor uptake. Clin Cancer Res. 2018;24(14):3309\u201316.","journal-title":"Clin Cancer Res"},{"key":"206_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.nucmedbio.2018.05.002","volume":"62\u201363","author":"G Vaidyanathan","year":"2018","unstructured":"Vaidyanathan G, Kang CM, McDougald D, Minn I, Brummet M, Pomper MG, et al. Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors. Nucl Med Biol. 2018;62\u201363:18\u201330.","journal-title":"Nucl Med Biol"},{"key":"206_CR19","doi-asserted-by":"publisher","first-page":"117040","DOI":"10.1016\/j.bmc.2022.117040","volume":"73","author":"G Valpreda","year":"2022","unstructured":"Valpreda G, Trachsel B, Vogel V, Schibli R, Mu L, Behe M. Dual MVK cleavable linkers effectively reduce renal retention of 111In-fibronectin-binding peptides. Bioorg Med Chem. 2022;73:117040.","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"206_CR20","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.2967\/jnumed.108.053249","volume":"49","author":"E Vegt","year":"2008","unstructured":"Vegt E, van Eerd JE, Eek A, Oyen WJ, Wetzels JF, de Jong M, et al. Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med. 2008;49(9):1506\u201311.","journal-title":"J Nucl Med"},{"issue":"4","key":"206_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00259-010-1685-9","volume":"38","author":"E Vegt","year":"2011","unstructured":"Vegt E, Melis M, Eek A, de Visser M, Brom M, Oyen WJ, et al. Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging. 2011;38(4):623\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"206_CR22","first-page":"2025","volume":"47","author":"D Wild","year":"2006","unstructured":"Wild D, Behe M, Wicki A, Storch D, Waser B, Gotthardt M, et al. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006;47(12):2025\u201333.","journal-title":"J Nucl Med"},{"issue":"6","key":"206_CR23","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1021\/acs.bioconjchem.9b00280","volume":"30","author":"M Zhang","year":"2019","unstructured":"Zhang M, Jacobson O, Kiesewetter DO, Ma Y, Wang Z, Lang L, et al. Improving the theranostic potential of exendin 4 by reducing the renal radioactivity through brush border membrane enzyme-mediated degradation. Bioconjug Chem. 2019;30(6):1745\u201353.","journal-title":"Bioconjug Chem"},{"issue":"9","key":"206_CR24","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1021\/acs.bioconjchem.1c00392","volume":"32","author":"M Zhang","year":"2021","unstructured":"Zhang M, Ye J, Xie Z, Yan Y, Wang J, Chen X. Optimization of enzymolysis clearance strategy to enhance renal clearance of radioligands. Bioconjug Chem. 2021;32(9):2108\u201316.","journal-title":"Bioconjug Chem"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-023-00206-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-023-00206-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-023-00206-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T13:04:41Z","timestamp":1700399081000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-023-00206-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1186\/s41181-023-00206-2","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"13 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were approved by the cantonal veterinary office of the canton Aargau (Switzerland) under the licence number AG75700 and were carried out in accordance with the Swiss law on animal protection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BT, GV and MB declare that they applied for a patent (Application No: 21 212 655.1) covering the double MVK cleavable linker strategy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}